Fulcrum Therapeutics Inc. (FULC) Misses Q4 EPS by 1c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q4 EPS of ($0.50), $0.01 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $685 thousand versus the consensus estimate of $1.89 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• EU opens antidumping review of Chinese silicon metal imports
• MongoDB (MDB) Tops Q2 EPS by 29c, Beats on Revenue; Offers FY37 Guidance